Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Tibet Rhodiola Pharmaceutical Holding Co
Operating Income
Tibet Rhodiola Pharmaceutical Holding Co
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Operating Income
¥1.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
31%
|
CAGR 10-Years
55%
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Operating Income
¥22.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
S
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Operating Income
¥8.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Operating Income
¥3.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Operating Income
¥2.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
21%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Operating Income
¥3.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Income?
Operating Income
1.2B
CNY
Based on the financial report for Dec 31, 2023, Tibet Rhodiola Pharmaceutical Holding Co's Operating Income amounts to 1.2B CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Operating Income growth rate?
Operating Income CAGR 10Y
55%
Over the last year, the Operating Income growth was 76%. The average annual Operating Income growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 39% over the past three years , 31% over the past five years , and 55% over the past ten years .